Summary The prevailing view on the role of glutathione in protein disulphidebond formation is that this tripeptide acts as a net reductant in the ER, either by maintaining ER oxidoreductases in a reduced state or by directly reducing nonnative disulphide bonds in substrate folding proteins
The most effective dosage, which improved red cell shape and decreased sickling, was 10 mg/ml
Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation
Stability Matters: Kojic acid is notoriously unstable and can turn brown or lose its effectiveness when exposed to air and light
Lpez-Guerrero VE, Posadas Y, Snchez-Lpez C, Smart A, Miranda J, Singewald K
